Cytokinetics (CYTK)
Developer of muscle-directed medicines led by MYQORZO for hypertrophic cardiomyopathy.
$67.25
After hours−0.36 (−0.53%)
At close$67.61(+0.07%)
Something off on this page? Send us feedback.
Next report
Nov 4, 26
in 43 days
EPS estimate
−$1.45
Revenue estimate
$39.9M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$1.26−$1.36−$1.12−$2.55−$1.50−$1.67−$1.50Pending
Estimate−$1.29−$1.41−$1.34−$1.59−$1.48−$1.67−$1.63−$1.45
Surprise+2.3%+3.5%+16.4%−60.4%−1.4%0.0%+8.0%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$16.9M$1.6M$66.8M$1.9M$17.8M$19.4M$28.6MPending
Estimate$14.3M$2.8M$2.1M$6.0M$6.9M$8.5M$17.6M$39.9M
Surprise+18.7%−43.4%+3,131.1%−68.0%+156.3%+127.2%+62.7%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | −$0.65 | — | — |
| Sep 2028 | −$2.55 | — | — |
| Jun 2028 | −$1.12 | — | — |
| Mar 2028 | −$1.36 | — | — |
| Dec 2027 | −$0.78 | — | — |
| Sep 2027 | −$1.23 | — | — |
| Jun 2027 | −$1.34 | — | — |
| Mar 2027 | −$1.38 | — | — |
| Dec 2026 | −$1.45 | — | — |
| Nov 2026 | −$1.45 | — | — |
| Aug 2026 | −$1.63 | −$1.50 | +8.0% |
| May 2026 | −$1.67 | −$1.67 | 0.0% |
| Feb 2026 | −$1.48 | −$1.50 | −1.4% |
| Nov 2025 | −$1.59 | −$2.55 | −60.4% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Oct 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Jul 2018 | |||
| Apr 2018 | |||
| Feb 2018 | |||
| Oct 2017 | |||
| Aug 2017 | |||
| Apr 2017 | |||
| Feb 2017 | |||
| Oct 2016 | |||
| Jul 2016 | |||
| Apr 2016 | |||
| Feb 2016 | |||
| Oct 2015 | |||
| Jul 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | −$0.65 | — | — | $44.7M | — | — | — |
| Sep 2028 | −$2.55 | — | — | $63.3M | — | — | — |
| Jun 2028 | −$1.12 | — | — | $58.7M | — | — | — |
| Mar 2028 | −$1.36 | — | — | $54.4M | — | — | — |
| Dec 2027 | −$0.78 | — | — | $177.7M | — | — | — |
| Sep 2027 | −$1.23 | — | — | $128.7M | — | — | — |
| Jun 2027 | −$1.34 | — | — | $90.2M | — | — | — |
| Mar 2027 | −$1.38 | — | — | $60.4M | — | — | — |
| Dec 2026 | −$1.45 | — | — | $58.3M | — | — | — |
| Nov 4, 2026 | −$1.45 | — | — | $39.9M | — | — | — |
| Aug 6, 2026 | −$1.63 | −$1.50 | +8.0% | $17.6M | $28.6M | +62.7% | −5.7% |
| May 5, 2026 | −$1.67 | −$1.67 | 0.0% | $8.5M | $19.4M | +127.2% | −2.9% |
| Feb 24, 2026 | −$1.48 | −$1.50 | −1.4% | $6.9M | $17.8M | +156.3% | −10.3% |
| Nov 5, 2025 | −$1.59 | −$2.55 | −60.4% | $6.0M | $1.9M | −68.0% | +1.9% |
| Aug 7, 2025 | |||||||
| May 6, 2025 | |||||||
| Feb 27, 2025 | |||||||
| Nov 6, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 8, 2024 | |||||||
| Feb 27, 2024 | |||||||
| Nov 2, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 4, 2023 | |||||||
| Mar 1, 2023 | |||||||
| Nov 3, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 4, 2022 | |||||||
| Feb 24, 2022 | |||||||
| Nov 3, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 6, 2021 | |||||||
| Feb 25, 2021 | |||||||
| Nov 4, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 6, 2020 | |||||||
| Mar 3, 2020 | |||||||
| Oct 31, 2019 | |||||||
| Aug 8, 2019 | |||||||
| May 9, 2019 | |||||||
| Feb 21, 2019 | |||||||
| Nov 1, 2018 | |||||||
| Jul 26, 2018 | |||||||
| Apr 26, 2018 | |||||||
| Feb 15, 2018 | |||||||
| Oct 26, 2017 | |||||||
| Aug 2, 2017 | |||||||
| Apr 27, 2017 | |||||||
| Feb 16, 2017 | |||||||
| Oct 27, 2016 | |||||||
| Jul 28, 2016 | |||||||
| Apr 28, 2016 | |||||||
| Feb 16, 2016 | |||||||
| Oct 29, 2015 | |||||||
| Jul 29, 2015 |